3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
41
Stomach Neoplasms
22
Esophageal Neoplasms
20
Esophageal Squamous Cell Carcinoma
19
Colorectal Neoplasms
12
Pancreatic Neoplasms
9
Liver Neoplasms
6
Cholangiocarcinoma
6
Biliary Tract Neoplasms
5
Advanced Gastric Cancer
5
Locally Advanced Gastric Cancer
4
Rectal Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Metastatic Gastric Adenocarcinoma
2
Locally Advanced Rectal Cancer
2
Liver Diseases
2
Gastrointestinal Neoplasms
2
Esophageal Diseases
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Advanced Gastric Adenocarcinoma
2
Unresectable Gallbladder Cancer
1
Turcot syndrome
1
Stomach Diseases
1
Stage IV Gastric Cancer With Metastasis
1
Second Line Treatment of Gastric Cancer
1
SHR-1210
1
Recurrence
1
Rectal Cancer Patients
1
Interventions
pembrolizumab
5
Nivolumab
5
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
sintilimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
danvatirsen
1
camrelizumab
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Immunoglobulin G
1
IMM-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
camrelizumab
×
Gastrointestinal
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled